April 17, 2015
SAN DIEGO — In this video, Susheel Kodali, MD, of Columbia University Medical Center, New York-Presbyterian Hospital, discusses the 30-day results from the SAPIEN 3 trial, presented at the American College of Cardiology Scientific Sessions.
The trial evaluated the next-generation, balloon-expandable SAPIEN 3 valve (Edwards Lifesciences) in a cohort of high-risk, inoperable and intermediate-risk patients. The study included two separate, single-arm registries, including 583 high-risk and inoperable patients with severe aortic stenosis in one arm and 1,076 intermediate-risk patients in the second arm. Kodali said that this is the first trial to provide data in the U.S. on intermediate-risk patients.